X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs GLENMARK PHARMA - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD GLENMARK PHARMA ALEMBIC LTD/
GLENMARK PHARMA
 
P/E (TTM) x 74.8 13.9 540.0% View Chart
P/BV x 2.8 3.9 71.6% View Chart
Dividend Yield % 0.4 0.3 123.4%  

Financials

 ALEMBIC LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-16
GLENMARK PHARMA
Mar-16
ALEMBIC LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs531,262 4.2%   
Low Rs29672 4.4%   
Sales per share (Unadj.) Rs4.7270.6 1.7%  
Earnings per share (Unadj.) Rs8.824.9 35.3%  
Cash flow per share (Unadj.) Rs9.034.4 26.2%  
Dividends per share (Unadj.) Rs0.152.00 7.5%  
Dividend yield (eoy) %0.40.2 176.6%  
Book value per share (Unadj.) Rs27.7151.3 18.3%  
Shares outstanding (eoy) m267.03282.16 94.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x8.73.6 243.4%   
Avg P/E ratio x4.738.9 12.0%  
P/CF ratio (eoy) x4.628.1 16.2%  
Price / Book Value ratio x1.56.4 23.2%  
Dividend payout %1.78.0 21.3%   
Avg Mkt Cap Rs m10,962272,778 4.0%   
No. of employees `000NA10.0 0.0%   
Total wages/salary Rs m23813,782 1.7%   
Avg. sales/employee Rs ThNM7,614.9-  
Avg. wages/employee Rs ThNM1,374.8-  
Avg. net profit/employee Rs ThNM700.2-  
INCOME DATA
Net Sales Rs m1,26076,340 1.7%  
Other income Rs m264356 74.1%   
Total revenues Rs m1,52476,696 2.0%   
Gross profit Rs m8314,172 0.6%  
Depreciation Rs m612,691 2.3%   
Interest Rs m01,789 0.0%   
Profit before tax Rs m28510,048 2.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m2,0960-   
Extraordinary Inc (Exp) Rs m-320-   
Tax Rs m63,028 0.2%   
Profit after tax Rs m2,3437,019 33.4%  
Gross profit margin %6.618.6 35.4%  
Effective tax rate %2.130.1 7.1%   
Net profit margin %185.99.2 2,021.8%  
BALANCE SHEET DATA
Current assets Rs m1,68959,096 2.9%   
Current liabilities Rs m48640,018 1.2%   
Net working cap to sales %95.425.0 381.8%  
Current ratio x3.51.5 235.2%  
Inventory Days Days21775 289.4%  
Debtors Days Days81119 68.0%  
Net fixed assets Rs m1,62439,075 4.2%   
Share capital Rs m534282 189.3%   
"Free" reserves Rs m5,96030,281 19.7%   
Net worth Rs m7,40442,703 17.3%   
Long term debt Rs m10424,873 0.4%   
Total assets Rs m8,010111,026 7.2%  
Interest coverage x950.76.6 14,367.9%   
Debt to equity ratio x00.6 2.4%  
Sales to assets ratio x0.20.7 22.9%   
Return on assets %29.37.9 368.7%  
Return on equity %31.616.4 192.5%  
Return on capital %31.317.5 178.6%  
Exports to sales %2.943.3 6.8%   
Imports to sales %28.97.4 388.4%   
Exports (fob) Rs m3733,044 0.1%   
Imports (cif) Rs m3645,672 6.4%   
Fx inflow Rs m3736,945 0.1%   
Fx outflow Rs m36561,066 0.6%   
Net fx Rs m-328-24,122 1.4%   
CASH FLOW
From Operations Rs m3463,449 10.0%  
From Investments Rs m-48-8,802 0.5%  
From Financial Activity Rs m-3016,986 -4.3%  
Net Cashflow Rs m-3934 -0.3%  

Share Holding

Indian Promoters % 64.0 48.3 132.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 6.9 2.9%  
FIIs % 9.7 34.4 28.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 10.5 248.6%  
Shareholders   54,701 56,727 96.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   CADILA HEALTHCARE  J.B.CHEMICALS  MERCK LTD  DISHMAN PHARMA  FULFORD INDIA  

Compare ALEMBIC LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Aug 18, 2017 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 8-QTR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS